Progenics Pharmaceuticals (PGNX)
Progenics Pharmaceuticals Revenue Growth: -6.78%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PGNX Revenue Growth Rankings
| Overall | 18th percentile | 3554 of 4363 |
| Sector | 19th percentile | 366 of 457 in Healthcare |
| Industry | 30th percentile | 87 of 126 in Biotechnology |
PGNX Revenue Growth Range, Past 5 Years
| Minimum | -92.71% | Mar 2010 |
| Maximum | 3128% | Jun 2011 |
| Average | 152.9% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these PGNX related companies
PGNX News
RT @Bud_Stocks LONG $PGNX and $MSHL and watching $CYCC if it breaks .57 with power Im long there to .63 then reevaluate. posted on the 27th
about 2 days ago by Bud_Stocks
about 2 days ago by Bud_Stocks
$PGNX Looks like we are not going to fill that nasty gap below or is this the bear flag. $8.70 is the level to watch.
about 6 days ago by VelocityTrader
about 6 days ago by VelocityTrader
$PGNX at support right now, watching for confirmation of bounce before rushing in to catch the knife.
about 15 days ago by VelocityTrader
about 15 days ago by VelocityTrader
$PGNX forms bearish "Megaphone Top" chart pattern. http://stks.co/3qUs
about 16 days ago by RecogniaEvents
about 16 days ago by RecogniaEvents
Listen to $PGNX Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3iQm
about 24 days ago by earningscast
about 24 days ago by earningscast
Progenics Pharmaceuticals Announces First Quarter 2012 Financial Results
May 08, 7:30AM GlobeNewswire
May 08, 7:30AM GlobeNewswire
$PGNX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3gLO
about 27 days ago by MarketBrief
about 27 days ago by MarketBrief
Progenics Pharmaceuticals to Host Conference Call to Review First Quarter Financial Results on May 8
May 04, 10:47AM GlobeNewswire
May 04, 10:47AM GlobeNewswire
$PGNX will most likely bleed down like $MAPP over the next few weeks
about 36 days ago by VelocityTrader
about 36 days ago by VelocityTrader
Salix (SLXP), Progenics (PGNX) Get FDA PDUFA Extension Date for RELISTOR
Apr 25, 8:01AM Street Insider
Apr 25, 8:01AM Street Insider
Brean Murray Carret & Co. Maintains Progenics Pharmaceuticals at Buy, Raises PT from $13 to $14
Mar 15, 11:14AM Benzinga
Mar 15, 11:14AM Benzinga
Progenics Pharmaceuticals, Inc. (PGNX) Misses Q4 EPS by 3c; Founder Maddon to Retire
Mar 15, 7:35AM Street Insider
Mar 15, 7:35AM Street Insider
Progenics Pharmaceuticals Announces Retirement of Founder Paul J. Maddon
Mar 15, 7:32AM GlobeNewswire
Mar 15, 7:32AM GlobeNewswire
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2011 Financial Results
Mar 15, 7:30AM GlobeNewswire
Mar 15, 7:30AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PGNX | 8.66 | -0.36 | -3.99% | 305.42M |
| PGN | 54.81 | +0.43 | +0.79% | 16.05B |
| PGI | 8.35 | +0.09 | +1.09% | 414.32M |
| PEGA | 31.05 | -0.30 | -0.96% | 1.185B |
| PEG | 31.18 | +0.43 | +1.40% | 15.56B |
| PEET | 59.48 | -0.43 | -0.72% | 792.01M |
| PEDH | 0.508 | +0.11 | +27.00% | 2.271M |
| PEBO | 18.83 | +0.16 | +0.86% | 199.40M |
| PEBK | 7.82 | +0.00 | +0.00% | 43.32M |
| PEB | 21.96 | +0.34 | +1.57% | 1.102B |
